Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Q2 2019 Biomarin Pharmaceutical Inc Earnings Call Transcript

Aug 01, 2019 / 08:30PM GMT
Operator

And good afternoon, and welcome to the BioMarin second quarter investor update. My name is Altecia, and I will be facilitating the audio portion of today's interactive broadcast. (Operator Instructions)

At this time, I would now like to turn this show over to Traci, Vice President of Investor Relations.

Traci McCarty
BioMarin Pharmaceutical Inc. - VP of IR

Thank you, Altecia. Thanks, everyone, for joining us today.

(technical difficulty)

Chairman and Chief Executive Officer; Hank Fuchs, President of Worldwide Research and Development; Dan Spiegelman, Executive Vice President and Chief Financial Officer; Jeff Ajer, Executive Vice President, Chief Commercial Officer; and Robert Baffi, President of Global Manufacturing and Technical Operations. Based on positive feedback from our last quarterly call, we intend to keep this call to an hour in length. If we do not get to your questions, please send an e-mail or give me a call and we'll get right back to you. Thank you for understanding. Now, I'd like to turn the call over to BioMarin's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot